abi-4334
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 11, 2022 (NCT05569941)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hepatitis B virusANTAGONIST
Hepatitis B virus antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06384131 | Phase 1 | May 8, 2024 | Assembly Biosciences |
| NCT05569941 | Phase 1 | Nov 11, 2022 | Assembly Biosciences, New Zealand Clinical Research |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Assembly Biosciences | For profit | 2 | 2 | 1 | 2022 |
| New Zealand Clinical Research | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1